Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Lenalidomide × Clear all Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1/2 Completed
55 enrolled 17 charts
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
Phase 2 Completed
45 enrolled 12 charts
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Phase 2 Completed
41 enrolled
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Phase 1/2 Completed
66 enrolled 13 charts
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
30 enrolled 12 charts
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Phase 2 Completed
36 enrolled 11 charts
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
Phase 1 Completed
8 enrolled
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Phase 2 Completed
50 enrolled 11 charts
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
27 enrolled
ThRiL
Phase 2 Completed
15 enrolled 12 charts
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
Phase 3 Completed
89 enrolled
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
Phase 3 Completed
317 enrolled 13 charts
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
Phase 2 Completed
6 enrolled 10 charts
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase 2 Completed
29 enrolled 9 charts
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
241 enrolled 31 charts
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
Phase 2 Completed
33 enrolled 8 charts
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Phase 1 Completed
20 enrolled
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase 2 Completed
34 enrolled 16 charts
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Phase 1 Completed
52 enrolled
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Phase 1 Completed
26 enrolled
ORIGIN
Phase 3 Completed
450 enrolled 25 charts
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
36 enrolled 7 charts
LLC0606
Phase 1/2 Completed
42 enrolled 11 charts
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
22 enrolled 6 charts
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
104 enrolled 18 charts
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
Phase 2 Completed
61 enrolled 5 charts
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Phase 1 Completed
21 enrolled 10 charts
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
Phase 1 Completed
37 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
45 enrolled 11 charts
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Phase 2 Completed
26 enrolled 7 charts
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 Completed
64 enrolled 7 charts
LenD
Phase 2 Completed
12 enrolled
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Phase 2 Completed
36 enrolled 7 charts
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
Phase 1/2 Completed
12 enrolled
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Phase 2 Completed
60 enrolled 5 charts
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
39 enrolled
Phase I BLR
Phase 1 Completed
28 enrolled
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
33 enrolled 8 charts
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
Phase 1/2 Completed
45 enrolled
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
45 enrolled 6 charts
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
Phase 1 Completed